Hyftor
What Hyftor is used for
Hyftor is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 years and older.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Hyftor
- Active substance
- sirolimus
- Disease area
- Angiofibroma; Tuberous Sclerosis
- Marketing authorisation holder
- Plusultra pharma GmbH
- Authorised in the EU since
- 2023
Official information
In the USA
In India
- Sirolimus: 15 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Hyftor used for?
Hyftor is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 years and older.
What is the active substance in Hyftor?
Hyftor contains sirolimus.
Who makes Hyftor?
The EU marketing authorisation holder is Plusultra pharma GmbH.
Is Hyftor an orphan medicine?
Yes. Hyftor is designated an orphan medicine in the EU, for a rare disease (Angiofibroma; Tuberous Sclerosis).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU